503B outsourcing facilities market seen reaching $9.81 billion by 2030

The Business Research Company says the global market for 503B outsourcing facilities will rise from $5.85 billion in 2025 to $9.81 billion by 2030, driven by drug shortages, sterile injectable demand and tighter compliance standards. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - 503B outsourcing facilities help hospitals, clinics and other providers secure sterile compounded drugs when supply is tight. - The market’s projected growth signals more reliance on centralized pharmaceutical manufacturing as drug shortages, surgical volume and outpatient care increase. - The forecast also points to stronger demand for FDA-registered facilities that meet current good manufacturing practices.

What happened: - The Business Research Company forecast the 503B outsourcing facilities market to grow from $5.85 billion in 2025 to $6.48 billion in 2026. - The company projected the market will reach $9.81 billion by 2030, reflecting a 10.9% CAGR from 2026 to 2030. - The report identifies 503B outsourcing facilities as compounding sites created under Section 503B of the U.S. Federal Food, Drug, and Cosmetic Act. - These facilities produce large quantities of sterile and non-sterile compounded medications for healthcare providers without individual patient prescriptions. - The facilities must register with the U.S. Food and Drug Administration and comply with cGMP. - The report was published July 15, 2026. - A free sample of the market report is available. - The full market report is also available.

The details: - The report links historical growth to widespread drug shortages, growing dependence on hospital-based compounding pharmacies, FDA’s creation of the 503B framework, expansion of hospital networks and centralized purchasing systems, and higher demand for sterile injectable drugs in clinical settings. - The forecast is supported by increased use of outpatient infusion and ambulatory care services, cost containment pressure on healthcare providers, stricter regulatory inspection standards, improved sterility assurance and quality validation, and consolidation among 503B facilities and contract manufacturers. - The report also cites stronger outsourcing tied to drug shortages, tighter enforcement of FDA current good manufacturing practices, rising hospital and clinic demand for sterile injectables, expanding group purchasing organization contracts, and a shift away from in-house hospital compounding. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - In 2025, North America held the largest share of the market. - Asia-Pacific is expected to post the fastest growth in the coming years.

Between the lines: - The forecast suggests 503B outsourcing is moving from a backstop for shortages to a more embedded part of healthcare supply chains. - More scrutiny and compliance requirements may favor larger or better-capitalized providers that can meet FDA and quality standards at scale. - The report’s emphasis on consolidation and purchasing contracts points to a market where scale and distribution access may matter as much as manufacturing capacity.

What's next: - The Business Research Company expects demand to keep rising as outpatient care expands and hospitals continue outsourcing sterile compounding. - Market structure may keep shifting toward centralized production, especially if drug shortages and compliance pressure persist. - Regional growth will likely remain uneven, with North America leading in share and Asia-Pacific growing fastest.